Penicillin allergy status and its effect on antibiotic prescribing, patient outcomes and antimicrobial resistance (ALABAMA) : protocol for a multicentre, parallel-arm, open-label, randomised pragmatic trial
© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ..
INTRODUCTION: Incorrect penicillin allergy records are recognised as an important barrier to the safe treatment of infection and affect an estimated 2.7 million people in England. Penicillin allergy records are associated with worse health outcome and antimicrobial resistance. The ALlergy AntiBiotics And Microbial resistAnce (ALABAMA) trial aims to determine if an intervention package, centred around a penicillin allergy assessment pathway (PAAP) initiated in primary care, is safe and effective in improving patient health outcomes and antibiotic prescribing.
METHODS AND ANALYSIS: The ALABAMA trial is a multicentre, parallel-arm, open-label, randomised pragmatic trial with a nested pilot study. Adults (≥18 years) with a penicillin allergy record and who have received antibiotics in the previous 24 months will be eligible for participation. Between 1592 and 2090 participants will be recruited from participating National Health Service general practices in England. Participants will be randomised to either usual care or intervention to undergo a pre-emptive PAAP using a 1:1 allocation ratio. The primary outcome measure is the percentage of treatment response failures within 28 days of an index prescription. 2090 and 1592 participants are estimated to provide 90% and 80% power, respectively, to detect a clinically important absolute difference of 7.9% in primary outcome at 1 year between groups. The trial includes a mixed-methods process evaluation and cost-effectiveness evaluation.
ETHICS AND DISSEMINATION: This trial has been approved by London Bridge Research Ethics Committee (ref: 19/LO/0176). It will be conducted in compliance with Good Clinical Practice guidelines according to the Declaration of Helsinki. Informed consent will be obtained from all subjects involved in the study. The primary trial results will be submitted for publication to an international, peer-reviewed journal.
TRIAL REGISTRATION: ISRCTN20579216.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
BMJ open - 13(2023), 9 vom: 04. Sept., Seite e072253 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Armitage, Kelsey Fiona [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-Bacterial Agents |
|---|
| Anmerkungen: |
Date Completed 06.09.2023 Date Revised 08.09.2023 published: Electronic ISRCTN: ISRCTN20579216 Citation Status MEDLINE |
|---|
| doi: |
10.1136/bmjopen-2023-072253 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361642644 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361642644 | ||
| 003 | DE-627 | ||
| 005 | 20231226210842.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/bmjopen-2023-072253 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1205.xml |
| 035 | |a (DE-627)NLM361642644 | ||
| 035 | |a (NLM)37666558 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Armitage, Kelsey Fiona |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Penicillin allergy status and its effect on antibiotic prescribing, patient outcomes and antimicrobial resistance (ALABAMA) |b protocol for a multicentre, parallel-arm, open-label, randomised pragmatic trial |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.09.2023 | ||
| 500 | |a Date Revised 08.09.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a ISRCTN: ISRCTN20579216 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. | ||
| 520 | |a INTRODUCTION: Incorrect penicillin allergy records are recognised as an important barrier to the safe treatment of infection and affect an estimated 2.7 million people in England. Penicillin allergy records are associated with worse health outcome and antimicrobial resistance. The ALlergy AntiBiotics And Microbial resistAnce (ALABAMA) trial aims to determine if an intervention package, centred around a penicillin allergy assessment pathway (PAAP) initiated in primary care, is safe and effective in improving patient health outcomes and antibiotic prescribing | ||
| 520 | |a METHODS AND ANALYSIS: The ALABAMA trial is a multicentre, parallel-arm, open-label, randomised pragmatic trial with a nested pilot study. Adults (≥18 years) with a penicillin allergy record and who have received antibiotics in the previous 24 months will be eligible for participation. Between 1592 and 2090 participants will be recruited from participating National Health Service general practices in England. Participants will be randomised to either usual care or intervention to undergo a pre-emptive PAAP using a 1:1 allocation ratio. The primary outcome measure is the percentage of treatment response failures within 28 days of an index prescription. 2090 and 1592 participants are estimated to provide 90% and 80% power, respectively, to detect a clinically important absolute difference of 7.9% in primary outcome at 1 year between groups. The trial includes a mixed-methods process evaluation and cost-effectiveness evaluation | ||
| 520 | |a ETHICS AND DISSEMINATION: This trial has been approved by London Bridge Research Ethics Committee (ref: 19/LO/0176). It will be conducted in compliance with Good Clinical Practice guidelines according to the Declaration of Helsinki. Informed consent will be obtained from all subjects involved in the study. The primary trial results will be submitted for publication to an international, peer-reviewed journal | ||
| 520 | |a TRIAL REGISTRATION: ISRCTN20579216 | ||
| 650 | 4 | |a Clinical Trial Protocol | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a clinical trial | |
| 650 | 4 | |a immunology | |
| 650 | 4 | |a infectious diseases | |
| 650 | 4 | |a primary care | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 650 | 7 | |a Penicillins |2 NLM | |
| 700 | 1 | |a Porter, Catherine E |e verfasserin |4 aut | |
| 700 | 1 | |a Ahmed, Shadia |e verfasserin |4 aut | |
| 700 | 1 | |a Cook, Johanna |e verfasserin |4 aut | |
| 700 | 1 | |a Boards, Jenny |e verfasserin |4 aut | |
| 700 | 1 | |a Bongard, Emily |e verfasserin |4 aut | |
| 700 | 1 | |a Butler, Christopher C |e verfasserin |4 aut | |
| 700 | 1 | |a Corfield, Kate |e verfasserin |4 aut | |
| 700 | 1 | |a Davoudianfar, Mina |e verfasserin |4 aut | |
| 700 | 1 | |a Galal, Ushma |e verfasserin |4 aut | |
| 700 | 1 | |a Howard, Philip |e verfasserin |4 aut | |
| 700 | 1 | |a Mujica-Mota, Ruben |e verfasserin |4 aut | |
| 700 | 1 | |a Saman, Razan |e verfasserin |4 aut | |
| 700 | 1 | |a Santillo, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Savic, Sinisa |e verfasserin |4 aut | |
| 700 | 1 | |a Shinkins, Bethany |e verfasserin |4 aut | |
| 700 | 1 | |a Tonkin-Crine, Sarah |e verfasserin |4 aut | |
| 700 | 1 | |a Wanat, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a West, Robert M |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Ly-Mee |e verfasserin |4 aut | |
| 700 | 1 | |a Pavitt, Sue |e verfasserin |4 aut | |
| 700 | 1 | |a Sandoe, Jonathan A T |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMJ open |d 2012 |g 13(2023), 9 vom: 04. Sept., Seite e072253 |w (DE-627)NLM215724372 |x 2044-6055 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2023 |g number:9 |g day:04 |g month:09 |g pages:e072253 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1136/bmjopen-2023-072253 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2023 |e 9 |b 04 |c 09 |h e072253 | ||